Physician profile
Robert H Thomas
NPI 1205899051
$4,743.39
in general payments reported to CMS, 2019-2025
30 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $731 · 2021: $843 · 2022: $499 · 2023: $750 · 2024: $815 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $620.30 | 2019-2023 | Seglentis, Livalo |
| Glaxosmithkline, LLC. | $532.21 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $474.50 | 2020-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $418.21 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $398.20 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $270.49 | 2021-2025 | |
| Abbvie INC. | $244.94 | 2021-2024 | Ubrelvy, Qulipta |
| Pfizer INC. | $198.28 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $193.59 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $188.89 | 2019-2023 | |
| Novo Nordisk INC | $161.25 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.62 | 2019-2021 | |
| Abbott Laboratories | $145.20 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Currax Pharmaceuticals LLC | $131.96 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $121.00 | 2023-2025 | Edarbi, Alvesco, Edarbi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $61.59 | 2021 | |
| Arbor Pharmaceuticals, INC. | $59.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.26 | 2019-2021 | |
| Redhill Biopharma INC. | $48.92 | 2020 | |
| Merck Sharp & Dohme LLC | $35.28 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Allergan, INC. | $34.55 | 2020 | |
| Edwards Lifesciences Corporation | $31.45 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.40 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.69 | 2021 | |
| Axsome Therapeutics, INC. | $23.18 | 2023 | Sunosi |
| Medicure Pharma INC. | $20.95 | 2021 | |
| Genzyme Corporation | $19.29 | 2020 | |
| Alnylam Pharmaceuticals INC. | $17.26 | 2020 | |
| Ibsa Pharma INC. | $16.41 | 2022 | |
| Saluda Medical Americas, INC. | $14.44 | 2025 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.